No photo of Jessica K Altman

View Scopus Profile

Jessica K Altman

  • 3253 Citations
20052021
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Certifications and Licenses

Medical Oncology
Hematology
Internal Medicine

Training Experience

2004Residency, University of Chicago Hospitals
2007Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

MD, University of Pittsburgh

… → 2001

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 36 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Acute Promyelocytic Leukemia Medicine & Life Sciences
Sirolimus Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Tretinoin Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Leukemia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2007 2021

Prot #AMV564-101: A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Altman, J. K.

Amphivena Therapeutics, Inc.

10/18/18 → 10/18/21

Project: Research project

Prot #BAY 1436032/19036: An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacok

Altman, J. K.

Covance Inc., Bayer HealthCare Pharmaceuticals, Inc.

2/22/18 → 6/1/19

Project: Research project

Prot #FF-10101-US101/201: A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

Altman, J. K.

Quintiles, Inc., FUJIFILM Pharmaceuticals U.S.A., Inc.

8/2/17 → 8/2/20

Project: Research project

Prot #1315.2: An Open-Label, Phase I/II Trial To Determine The Maximum Tolerated Dose And Investigate Safety, Pharmacokinetics And Efficacy Of BI 836858 In Combination With Decitabine In Patients With Acute Myeloid Leukemia

Altman, J. K.

Boehringer Ingelheim Pharmaceuticals, Inc.

2/13/17 → 2/13/20

Project: Research project

Prot #CC-90009-AML-001: A Phase 1, Open-Label, Dose-Finding Study Of CC-90009, A Novel Cereblon E3 Ligase Modulating Drug, In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia

Altman, J. K.

ICON Clinical Research, LLC, Celgene Corporation

10/18/16 → 10/18/19

Project: Research project

Research Output 2005 2019

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

Litzow, M. R., Wang, X. V., Carroll, M. P., Karp, J. E., Ketterling, R. P., Zhang, Y., Kaufmann, S. H., Lazarus, H. M., Luger, S. M., Paietta, E. M., Pratz, K. W., Tun, H. W., Altman, J. K., Broun, E. R., Rybka, W. B., Rowe, J. M. & Tallman, M. S., Jan 1 2019, In : American Journal of Hematology. 94, 1, p. 111-117 7 p.

Research output: Contribution to journal › Article

alvocidib
Mitoxantrone
Cytarabine
Acute Myeloid Leukemia
Topotecan
1 Citations

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Levis, M. J., Perl, A. E., Altman, J. K., Gocke, C. D., Bahceci, E., Hill, J., Liu, C., Xie, Z., Carson, A. R., McClain, V., Stenzel, T. T. & Miller, J. E., Apr 24 2018, In : Blood advances. 2, 8, p. 825-831 7 p.

Research output: Contribution to journal › Article

Residual Neoplasm
Acute Myeloid Leukemia
Mutation
DNA
fms-Like Tyrosine Kinase 3
1 Citations

Chronic myeloid leukemia, version 1.2019

Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., Hobbs, G., Jagasia, M., Kantarjian, H. M., Maness, L., Metheny, L., Moore, J. O., Pallera, A., Pancari, P., Patnaik, M., Purev, E. & 10 othersRose, M. G., Shah, N. P., Smith, B. D., Snyder, D. S., Sweet, K. L., Talpaz, M., Thompson, J., Yang, D. T., Gregory, K. M. & Sundar, H., Sep 1 2018, In : JNCCN Journal of the National Comprehensive Cancer Network. 16, 9, p. 1108-1135 28 p.

Research output: Contribution to journal › Review article

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Chromosomes, Human, Pair 22
32 Citations

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML

DiNardo, C. D., Stein, E. M., De Botton, S., Roboz, G. J., Altman, J. K., Mims, A. S., Swords, R., Collins, R. H., Mannis, G. N., Pollyea, D. A., Donnellan, W., Fathi, A. T., Pigneux, A., Erba, H. P., Prince, G. T., Stein, A. S., Uy, G. L., Foran, J. M., Traer, E., Stuart, R. K. & 20 othersArellano, M. L., Slack, J. L., Sekeres, M. A., Willekens, C., Choe, S., Wang, H., Zhang, V., Yen, K. E., Kapsalis, S. M., Yang, H., Dai, D., Fan, B., Goldwasser, M., Liu, H., Agresta, S., Wu, B., Attar, E. C., Tallman, M. S., Stone, R. M. & Kantarjian, H. M., Jun 21 2018, In : New England Journal of Medicine. 378, 25, p. 2386-2398 13 p.

Research output: Contribution to journal › Article

Isocitrate Dehydrogenase
Acute Myeloid Leukemia
Confidence Intervals
Mutation
Safety
5 Citations

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

Altman, J. K., Foran, J. M., Pratz, K. W., Trone, D., Cortes, J. E. & Tallman, M. S., Feb 1 2018, In : American Journal of Hematology. 93, 2, p. 213-221 9 p.

Research output: Contribution to journal › Article

Consolidation Chemotherapy
Induction Chemotherapy
Acute Myeloid Leukemia
Standard of Care
Drug Therapy